Physician profile
Rupinder Mann
NPI 1982799813
$2,352.99
in general payments reported to CMS, 2019-2025
31 companies · $409 in 2025
The $409 reported for 2025 was more than what 75% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $121 · 2021: $162 · 2022: $441 · 2023: $505 · 2024: $716 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $346.19 | 2022-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $316.81 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Boston Scientific Corporation | $210.42 | 2023-2024 | Exalt Model D, Ams 700 |
| Lilly USA, LLC | $194.55 | 2022-2025 | Mounjaro, Emgality, Jardiance |
| Inspire Medical Systems, INC. | $125.00 | 2022 | |
| Intercept Pharmaceuticals, INC. | $120.52 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.35 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $81.15 | 2024-2025 | Farxiga |
| Shield Therapeutics INC | $68.52 | 2024 | |
| Smith+Nephew, INC. | $67.87 | 2023 | Grafix Pl |
| Xeris Pharmaceuticals, INC. | $65.10 | 2024 | Gvoke Hypopen |
| Novo Nordisk INC | $63.54 | 2023-2025 | Wegovy |
| Pfizer INC. | $61.20 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $54.78 | 2022 | |
| Neurocrine Biosciences, INC. | $54.57 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $48.55 | 2025 | Fanapt |
| Exact Sciences Corporation | $42.29 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $39.81 | 2023 | Jynarque, Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.62 | 2023-2025 | Jardiance, Tradjenta |
| Corium, LLC | $38.55 | 2022 | |
| Biogen, INC. | $24.99 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.88 | 2023 | |
| Si-Bone, INC. | $22.27 | 2023 | |
| Metacel Pharmaceuticals LLC | $21.13 | 2023 | Ozobax |
| Scpharmaceuticals INC. | $20.98 | 2023 | |
| Merck Sharp & Dohme LLC | $19.92 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.58 | 2023 | Xarelto |
| Abbvie INC. | $18.80 | 2023 | |
| Acella Pharmaceuticals, LLC | $15.19 | 2025 | NP Thyroid 60 |
| Philips North America LLC | $14.78 | 2025 | Respiratory |
| Amarin Pharma, INC. | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupinder Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.